Press Release

Grand News Network | October 24, 2023

Tourmaline Bio Director Awarded $478K Worth of Stock Options

AARON KANTOFF, Director at Tourmaline Bio (NASDAQ:TRML), reported a large acquisition of company stock options on October 24, according to a new SEC filing.

What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that KANTOFF, Director at Tourmaline Bio, a company in the Health Care sector, was just awarded stock options worth 47,890 shares of TRML. The options give KANTOFF the right to buy the company's stock at $2.08 per share.

Tourmaline Bio shares are trading up 0.95% at $9.55 at the time of this writing on Tuesday morning. Since the current price is $9.55, this makes KANTOFF's 47,890 shares worth $478,900.

Now trade stocks online ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner

More to read